Akari Therapeutics, Plc
Akari Therapeutics, Plc
Your view on AKTX
Overview
What the company does, where it operates, and who runs it.
About Akari Therapeutics, Plc
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Abizer Gaslightwala
- Headquarters
- 75/76 Wimpole Street, London, GB
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Abizer Gaslightwala
- Headquarters
- 75/76 Wimpole Street, London, GB
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases.
Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid.
Akari Therapeutics, Plc is based in London, the United Kingdom.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Akari Therapeutics, Plc from FRC's valuation model, read against the market price. AKTX last traded at $6.80; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Akari Therapeutics, Plc. Starting points for Akari Therapeutics, Plc: EPS -$8.85, beta 1.47 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Akari Therapeutics, Plc. Akari Therapeutics, Plc does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Akari Therapeutics, Plc. Trailing twelve-month EPS for Akari Therapeutics, Plc stands at -$8.85. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$24.75
average of analysts' targets
Analyst Ratings
- Strong Buy0
- Buy7
- Hold1
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | -$1.52 | -$2.09 | -$9.86 | -$5.49 |
| Low estimate | -$1.52 | -$2.09 | -$9.86 | -$5.49 |
| High estimate | -$1.52 | -$2.09 | -$9.86 | -$5.49 |
| No. of analysts | 1 | 1 | 1 | 1 |
| Year-ago EPS | -$2.991 | -$9.741 | -$20,800.001 | — |
| Growth | — | — | — | — |
1Year-ago EPS includes one-time items; growth not shown.
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $0.00 | $0.00 | $9.58M | $0.00 |
| Low estimate | $0.00 | $0.00 | $9.58M | $0.00 |
| High estimate | $0.00 | $0.00 | $9.58M | $0.00 |
| No. of analysts | 0 | 0 | 2 | 0 |
| Year-ago revenue | $0.00 | $0.00 | $0.00 | — |
| Growth | — | — | — | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from Benzinga; as of Nov 16, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Akari Therapeutics, Plc. Akari Therapeutics, Plc has reported as a listed company since 2014. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- CDTCDT Equity Inc.Biotechnology$181,934
- DRMADermata Therapeutics, Inc.Biotechnology$3M
- MSPRMSP Recovery, Inc.Medical - Healthcare Information Services$1,377
- PBMPsyence Biomedical Ltd.Biotechnology$59,815
- PPBTPurple Biotech Ltd.Biotechnology$225,077
- REVBRevelation Biosciences, Inc.Biotechnology$2M
- SYRSSyros Pharmaceuticals, Inc.Biotechnology$21,464
- VINCVincerx Pharma, Inc.Biotechnology$52,343
More Biotechnology companies
- PTGXProtagonist Therapeutics, Inc.NASDAQ$8.5B
- PTHSPelthos Therapeutics Inc.AMEX$29M
- PTIXProtagenic Therapeutics, Inc.NASDAQ$470,654
- PTNPalatin Technologies, Inc.NASDAQ$11M
- PTX.AXPrescient Therapeutics LimitedASX
- PULMPulmatrix, Inc.NASDAQ$5M
- PVCTProvectus Biopharmaceuticals, Inc.OTC$19M
- PVLAPalvella Therapeutics, Inc.NASDAQ$2.2B
- PXMDPaxMedica, Inc. Common StockOTC$37,879
- PXXLFPoxel S.A.OTC$13M
- PYC.AXPYC Therapeutics LimitedASX
- PYPDPolyPid Ltd.NASDAQ$127M
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Akari Therapeutics, Plc, and how their positions are changing. At a $15.6M market value, institutional positions materially move Akari Therapeutics, Plc's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Akari Therapeutics, Plc executives and directors. Shares of Akari Therapeutics, Plc have traded between $0.47 and $1.73 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Akari Therapeutics, Plc. Coverage tracks Akari Therapeutics, Plc within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Akari Therapeutics, Plc.